Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b-Reference-Cited by-同舟云学术

Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b

Published:2012-12-19 Issue:1 Volume:28 Page:51-56
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:J Gastroenterol Hepatol

Author:

Atsukawa Masanori¹,Tsubota Akihito²,Kondo Chisa¹,Itokawa Norio³,Narahara Yoshiyuki³,Nakatsuka Katsuhisa³,Hashimoto Satomi³,Fukuda Takeshi³,Matsushita Yoko³,Kidokoro Hideko³,Kobayashi Tamaki³,Kanazawa Hidenori³,Sakamoto Choitsu³

Affiliation:

1. Division of Gastroenterology; Department of Internal Medicine; Nippon Medical School Chiba Hokusoh Hospital; Chiba

2. Institute of Clinical Medicine and Research (ICMR); Jikei University School of Medicine; Chiba

3. Division of Gastroenterology; Department of Internal Medicine; Nippon Medical School; Tokyo; Japan

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1440-1746.2012.07267.x/fullpdf

Reference34 articles.

1. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

2. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N. Engl. J. Med.,2002

3. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection;McHutchison;N. Engl. J. Med.,2009

4. Identifying HCV genotype 1 patients at risk of relapse;Deschenes;Eur. J. Gastroenterol. Hepatol.,2010

5. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response;Ferenci;Gastroenterology,2010

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Statins in Chronic Liver Disease: Review of the Literature and Future Role;Seminars in Liver Disease;2024-05

2. Lipid metabolism in patients with chronic hepatitis C, non-alcoholic fatty liver disease and obesity under the influence of treatment;INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine);2024-04-19

3. Genetic and pharmacological perturbation of hepatitis-C virus entry;Current Opinion in Virology;2023-10

4. Safety of Statins and Nonstatins for Treatment of Dyslipidemia;Endocrinology and Metabolism Clinics of North America;2022-09

5. Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity;Cells;2021-06-29